RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Year: 2020
Type: review
Abstract: ) have the same impact on RAS signaling and function. The role of the nonmutated, wild-type RAS proteins in the context of mutant RAS is increasingly considered to be targetable, with reports of strategies that directly disrupt either the RAS interaction with activating guanine nucleotide exchange factors (GEFs) or receptor tyrosine kinase-mediated and GEF-dependent RAS activation (such as by targeting the scaffolding phosphatase SHP2). Last, the development of agents that target downstream effectors of RAS signaling has advanced substantially. In this review, we highlight some important trends in the targeting of RAS proteins in cancer.
Source: Science Signaling
Authors: Clint A. Stalnecker, Channing J. Der
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: Biological Activity of Ras Oncogenes, Defining RAS isoform- and mutation-specific roles in oncogenesis, Targeting undruggable RAS for cancer treatment, Integrated Training in Cancer Model Systems, Washington University SPORE in Pancreatic Cancer, G5028106406, SPORE in Gastrointestinal Cancer, Defining the contributions of WT RAS in RAS-mutant lung cancer, Identification of synthetic lethal interactors in pancreatic cancer
OpenAlex ID: W3013112801